We have previously described a human immunodeficiency virus type 1 (HIV-1) proviral clone, pL2, derived from defective viral particles with higher fusogenicity than the prototypic NL4-3 virus. In this study, we attempted to determine the region that confers the enhanced fusion activity by creating envelope recombinants between pL2 and pNL4-3, as well as point mutants based on pNL4-3. The results indicate that amino acid 36 of gp41 is key for the fusogenic activity and infectivity enhancement and that glycine 36 (36G) of gp41 in pL2 is conserved in nearly all HIV-1 isolates except for pNL4-3. The mutation 36G3D in a primary-isolate-derived Env decreased syncytium-forming activity and infectivity. The assays for cell-cell fusion and viral binding suggested that the enhanced fusion mediated by the 36D3G mutation is not due to increased binding efficiency but is directly due to actual enhancement of viral fusion activity. Interestingly, this amino acid position is exactly equivalent to that at which the mutation of HIV-1 isolates that have escaped from a fusion inhibitor, enfuvirtide (T-20), has been frequently observed. The correlation between these previous findings and our findings was suggested by structural analysis. Our finding, therefore, has implications for a molecular basis of the viral escape from this drug.The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env), which determines viral tropism, is initially synthesized as a single polypeptide precursor, gp160, forming trimers (46). Subsequently, this Env precursor is cleaved proteolytically into a heavily glycosylated surface subunit known as gp120 and a transmembrane subunit known as gp41, which are associated by noncovalent bonds in an oligomeric structure on the surface of the virion (10,18,31). On the target cell surface, the gp120 surface protein binds to CD4 and a coreceptor, leading to a conformational change in gp120 that alters gp120-gp41 interactions (23,47). This binding event triggers membrane fusion, which requires functions of gp41 ectodomain. The gp41 ectodomain contains a hydrophobic amino-terminal fusion peptide, followed by an amino-terminal and carboxy-terminal leucine/isoleucine heptad repeat domain with a helical structure (N-peptide helix and C-peptide helix, respectively) (3,6,26,36,43). Fusion is first induced by insertion of the fusion peptide at the amino terminus of gp41 into the host cell membrane, after which this region is brought into close proximity to the transmembrane domain of gp41. This is attained via the fusion-active conformation of a coiled-coil structure composed of internal triple-stranded N-peptide helices paired with antiparallel outer C-peptide helices packed along hydrophobic grooves, thus forming a six-helix bundle (7,43).The fusion inhibitor enfuvirtide (also known as T-20), a peptide based on the sequence of the C-peptide helix in gp41, blocks formation of the six-helix bundle and thus prevents membrane fusion (8,27,45). A mutation in the N-peptide helix of gp41, specifically, an asparti...